Dianthus Therapeutics, Inc. /DE/ Increase (Decrease) in Other Operating Assets
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Increase (Decrease) in Other Operating Assets of $940.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in other operating assets for the quarter ending 2026-06-30 was -$1.18M, a 177.62% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $2.12M.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $207.00K, a 95.90% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$89.00K, a 105.48% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in other operating assets for fiscal 2025 was -$358.00K, a 104.39% decline from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in other operating assets for fiscal 2024 was $8.16M, a 694.84% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in other operating assets for fiscal 2023 was $1.03M, a 3212.90% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in other operating assets for fiscal 2022 was $31.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $940.00K 10-Q · filed 2026-08-04 | $1.15M derived: sum of 3 quarters · filed 2026-08-04 | $1.06M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.12M 10-Q · filed 2026-05-05 | $2.33M derived: sum of 2 quarters · filed 2026-05-05 | $2.24M derived: sum of 3 quarters · filed 2026-05-05 | $3.77M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $118.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.64M derived: sum of 3 quarters · filed 2026-08-04 | -$358.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | -$89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.44M derived: sum of 2 quarters · filed 2026-08-04 | -$565.00K 10-Q · filed 2025-11-05 | $4.49M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$476.00K 10-Q · filed 2026-08-04 | $4.58M derived: sum of 3 quarters · filed 2026-08-04 | $6.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$2.00M 10-Q · filed 2026-05-05 | $3.05M derived: sum of 2 quarters · filed 2026-05-05 | $4.68M derived: sum of 3 quarters · filed 2026-05-05 | $6.51M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.68M derived: sum of 2 quarters · filed 2026-03-09 | $8.51M derived: sum of 3 quarters · filed 2026-03-09 | $8.16M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.45M derived: sum of 2 quarters · filed 2025-11-05 | $3.11M 10-Q · filed 2025-11-05 | $4.15M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.49M 10-Q · filed 2025-08-07 | $2.52M derived: sum of 3 quarters · filed 2025-08-07 | $2.53M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$343.00K 10-Q · filed 2025-05-12 | $694.00K derived: sum of 2 quarters · filed 2025-05-12 | $696.00K derived: sum of 3 quarters · filed 2025-05-12 | $689.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.04M derived: sum of 2 quarters · filed 2025-03-11 | $1.03M derived: sum of 3 quarters · filed 2025-03-11 | $1.03M 10-K · filed 2025-03-11 |
| 2023-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$5.00K derived: sum of 2 quarters · filed 2024-11-07 | -$10.00K 10-Q · filed 2024-11-07 | -$28.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$12.00K 10-Q · filed 2024-08-08 | -$30.00K derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$5.00K 10-Q · filed 2024-05-09 | -$23.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $31.00K 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $49.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $30.00K 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |